{
    "clinical_study": {
        "@rank": "67153", 
        "arm_group": [
            {
                "arm_group_label": "Primary Breast Tumor", 
                "description": "Primary breast tumor were test for HER2/neu status."
            }, 
            {
                "arm_group_label": "Axillary Lymph Nodes.", 
                "description": "Axillary Lymph Nodes were tested for HER2/neu status."
            }
        ], 
        "biospec_descr": {
            "textblock": "Paraffin embedded tissue blocks of primary breast tumor and axillary lymph nodes"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine discordant HER2/neu status of primary breast tumor\n      and metastatic breast cancer cells at regional lymph nodes in node positive breast cancer\n      patients."
        }, 
        "brief_title": "Discordant HER2/Neu Status of Breast Cancer.", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Malignant Neoplasm of Breast.", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "HER2/neu status of primary breast tumor and axillary lymph nodes were tested by IHC\n      staining. In the cases of equivocal result of IHC, FISH test were performed.\n\n      The result of HER2/neu status between primary breast tumor and axillary lymph node were\n      analyzed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Breast cancer patients stage I,II and III with axillary lymph nodes metastasis.\n\n        Exclusion Criteria:\n\n          -  Breast cancer patients stage I,II and III without axillary lymph nodes metastasis."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "25 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Breast Cancer Patients Stage I,II and III."
            }
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935739", 
            "org_study_id": "30_2013RC_IN318"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ratchathewi", 
                    "country": "Thailand", 
                    "state": "Bangkok", 
                    "zip": "10400"
                }, 
                "name": "National Cancer Institute , Thailand."
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_groups": "2", 
        "official_title": "Discordant HER2/Neu Status Between Primary Tumor and Axillary Lymph Node in Breast Cancer Patients.", 
        "overall_official": {
            "affiliation": "National Cancer Institute, Thailand", 
            "last_name": "AKANIST PIYAPANT, MD.,FRCST.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ministry of Public Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Association of HER2/neu status between primary breast tumor and axillary lymph nodes was analyzed by using the \u03c72 test", 
            "measure": "Association of HER2/neu status between primary breast tumor and axillary lymph nodes", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year"
        }, 
        "reference": [
            {
                "PMID": "15317891", 
                "citation": "Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91."
            }, 
            {
                "PMID": "19914540", 
                "citation": "Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast. 2009 Oct;18 Suppl 3:S38-40. doi: 10.1016/S0960-9776(09)70270-X."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935739"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cancer Institute, Thailand", 
            "investigator_full_name": "AKANIST  PIYAPANT, MD.,FRCST.", 
            "investigator_title": "Surgical Oncologist.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "National Cancer Institute, Thailand", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute, Thailand", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "1 Year", 
        "verification_date": "September 2013"
    }
}